IL6 and type 1 diabetes mellitus: Other studies reported that in patients with T1DM and T2DM, the combination of an SGLT2i and metformin increased levels of the antioxidants (TAS, SOD, and GPx), and prooxidants [AOPP, isoprostanes, and advanced glycation end-products (AGEs)], as well as inflammatory parameters [C-reactive protein (CRP), IL-6], but also reduced NAFLD fibrosis score [48,49,50].